Windlas Biotech Ltd. IPO
Windlas Biotech Ltd.
IPO Listing Details
Listed On
BSE & NSE
Listed On
Issue Price
₹460
Issue Price
Listing Price
₹439
Listing Price
Listing Gains
-₹21.00 (-4.57%)
Listing Gains
IPO Details
Bidding Dates
04 Aug - 06 Aug '21
Bidding Dates
Min. Investment
₹13,440
Min. Investment
Lot Size
30.00
Lot Size
Price Range
₹448 - ₹460
Price Range
Issue Size
391 Cr
Issue Size
Subscription Rate
- Retail Individual Investor24.11x
- Non-Institutional Investor15.73x
- Qualified Institutional Buyers24.40x
- Employees0.00x
About Company
The Rs 401.53-crore Windlas Biotech IPO opened for subscription from Aug 4-6, 2021. The book built issue consists of a fresh equity issue worth Rs. 165 crore and an offer for sale (OFS) of Rs. 236.54 crore at the upper cap by existing selling shareholders. The company has already raised up to Rs 120.46 crore through the anchor book launched on August 3, a day before the issue opening. The issue is priced at Rs 448 to Rs 460 per equity share.
Windlas Biotech is a leading domestic pharmaceutical company that offers various CDMO-based services, such as licensing, commercial manufacturing, product discovery, product development, and manufacturing of general products and complex products. Leading pharma companies like Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals and Systopic Laboratories are some of the marquee customers of Windlas Biotech. The company's Dehradun facility has an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/sachets, and 61.08 million liquid bottles.
Windlas Biotech Ltd. IPO Latest News and Subscription Status Today (Live)
The Windlas Biotech IPO is subscribed 22.44 times. The public issue subscribed 24.22 times in the retail category, 24.40 times in the QIB category, and 15.73 times in the NII category
Why should you invest in Windlas Biotech Ltd. IPO?
The issue is priced at 52 times its earnings (EPS of Rs 8.7 per share) at an upper price band of Rs 460 per share, which makes the issue aggressively priced. Windlas Biotech is one of the leading contract development and manufacturing organisation (CDMO) in India with a focus on the chronic therapeutic category. The company's innovative portfolio comprises complex generic products supported by robust R&D capabilities. The company has also forged long-term relationships with leading Indian pharmaceutical companies.
Windlas Biotech Ltd. IPO - SWOT Analysis
Windlass Biotech provides a comprehensive range of CDMO services from product discovery, product development, licensing, and commercial manufacturing of an innovative range of generic products, including complex generics. Its long-term relationship with leading Indian pharmaceutical companies bodes well for the company. The company has a consistent track record in terms of its financial performance.
However, since the company depends on the success of its relationships with its CDMO customers, any adverse developments or inability to enter into or maintain such relationships could hurt their business, results of operations and financial condition. The pharmaceutical market is subject to extensive regulation. Failure to comply with regulatory requirements in any pharmaceutical market could adversely affect their business in that market, results of operations and financial condition.
How to apply for Windlas Biotech Ltd. IPO?
You can apply for the Windlas Biotech Ltd. IPO in these ways:
UPI
Link your personal bank A/C to a trusted UPI ID and map it with your TradeSmart account. Now, proceed further to book your IPO. On acceptance of the mandate, the bid amount will get blocked in your bank account Learn more.
Demat Account
1. If you are an Existing TradeSmart demat account holder and wish to apply for an Windlas Biotech Ltd. click here.
2. If you don't have a TradeSmart Account? Sign up.
